Sumanta K. Pal, MD, of City of Hope, discusses phase II results from the SWOG 1500 study, which showed that compared with crizotinib and savolitinib, cabozantinib was the only agent that prolonged progression-free survival vs sunitinib in patients with metastatic papillary renal cell carcinoma (Abstract 270).
A spirited discussion ensued when we asked Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Thomas Powles, MD, PhD, of Cancer Research UK Bart...
Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses phase II results from the RETAIN BLADDER study, which sequenced bladder tumor samples while treating patients with ne...
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carci...
Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, discusses phase III results from the EV-301 trial, which showed that enfortumab vedotin is the first therapy to de...
Monika Joshi, MD, of Penn State Hershey Cancer Institute, discusses phase II results from the DUART study, which explored the efficacy of concurrent durvalumab, a checkpoint ...